Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Trial of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma

NCT00580320 is registered in ClinicalTrials.gov with Virginia Commonwealth University as lead sponsor.

NCT NCT00580320
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00580320 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Trial of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma
Lead sponsor
Virginia Commonwealth University
Phase
Phase 1
Overall status
Completed
Start date
September 30, 2004
Completion date
November 30, 2013
Enrollment
17 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoid tumors, melanoma, parathyroid carcinoma, small cell carcinoma of the lung, soft tissue sarcoma